Comparative Pharmacology
Head-to-head clinical analysis: DELTALIN versus RAYALDEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTALIN versus RAYALDEE.
DELTALIN vs RAYALDEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Rayaldee (calcifediol) is a vitamin D3 analog that is converted to the active hormone calcitriol by 1-alpha-hydroxylase in the kidney. It acts as a vitamin D receptor agonist, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and suppressing parathyroid hormone (PTH) secretion. In CKD patients, it lowers elevated PTH levels.
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
30 mcg orally once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Terminal elimination half-life is approximately 14-19 hours, reflecting the extended-release formulation designed for once-daily dosing.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Primarily fecal via biliary excretion (70-80%); renal excretion accounts for <10% of total clearance.
Category C
Category C
Vitamin D Analog
Vitamin D Analog